Rhythm Pharmaceuticals (RYTM)
Markets IMCIVREE and develops MC4R agonists for rare neuroendocrine obesity disorders.
$99.27
After hours−0.16 (−0.16%)
At close$99.43(+0.60%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 112.97% | 77.78M shares | |
|---|---|---|---|
| 312 holders · as of Jun 30, 2026 | |||
| Insiders | 0.79% | 543.3K shares | |
| 13 holders · as of Sep 14, 2026 | |||
| Adds to | 113.76% | ||
68.85M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 113.76%; nothing is left for Other.
13F, as of Jun 30, 2026
312 holders · 77.78M shares · 65 new positions · 172 increased · 100 reduced · 45 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 6.67M | 9.68% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.16M | 8.94% | −80.2K | Aug 7, 2026 |
| Baker Bros. Advisors LP | 5.60M | 8.14% | 0 | Aug 14, 2026 |
| Primecap Management Co/CA/ | 3.17M | 4.60% | −248.7K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 3.14M | 4.56% | +96.2K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 3.01M | 4.37% | +38.2K | Aug 13, 2026 |
| JPMorgan Chase & Co | 2.65M | 3.85% | +1.10M | Aug 12, 2026 |
| Perceptive Advisors LLC | 2.59M | 3.76% | +212.5K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.90% | 6.67M | 13G | Feb 17, 2026 |
| Baker Bros. Advisors LP | 8.90% | 5.60M | 13G | May 15, 2025 |
| BlackRock, Inc. | 6.90% | 4.36M | 13G | Apr 24, 2025 |
| Primecap Management Co/CA/ | 5.21% | 3.48M | 13G | Feb 12, 2026 |
| Perceptive Advisors LLC | 5.10% | 3.52M | 13G | May 15, 2026 |
| Vanguard Capital Management | 5.02% | 3.43M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 14, 2026 | David P. Meekerdirector, officer: President and CEO | Sale · 5 lots | 50,000 | $102.67 | 239,258 |
| Aug 31, 2026 | Hunter C. Smithofficer: Chief Financial Officer | Sale · 3 lots | 62,774 | $105.46 | 114,024 |
| Aug 13, 2026 | Alastair Garfieldofficer: Chief Scientific Officer | Sale · 4 lots | 7,763 | $117.57 | 2,295 |
| Aug 13, 2026 | Joseph Shulmanofficer: Chief Technical Officer | Sale | 5,079 | $119.75 | 15,915 |
| Aug 13, 2026 | Jennifer Kayden Leeofficer: EVP, Head of North America | Sale | 75,834 | $117.38 | 0 |
| Aug 12, 2026 | Yann Mazabraudofficer: EVP, Head of International | Sale · 6 lots | 57,000 | $116.15 | 55,655 |
| Jun 22, 2026 | Lynn A. Tetraultdirector | Sale | 37,000 | $100.32 | 7,000 |
| May 15, 2026 | Christopher Paul Germanofficer: Corporate Controller & CAO | Sale | 4,643 | $92.21 | 0 |
| Mar 4, 2026 | Christopher Paul Germanofficer: Corporate Controller & CAO | Sale | 5,614 | $89.56 | 160 |
| Feb 19, 2026 | Hunter C. Smithofficer: Chief Financial Officer | Sale · 4 lots | 4,385 | $101.26 | 110,512 |
House and Senate disclosures
Not reported.